Trial reportJournal of hematology & oncology2014
Long-term follow-up of cytogenetically normal CEBPA-mutated AML.
Trial report in Journal of hematology & oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML.Blood cancer journal · 2025Article
- Telomere integrated scoring system of myelodysplastic syndrome.Journal of clinical laboratory analysis · 2023Article
- RUNX1/CEBPA Mutation in Acute Myeloid Leukemia Promotes Hypermethylation and Indicates for Demethylation Therapy.International journal of molecular sciences · 2022Article
- Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis.Translational cancer research · 2022Article
- Technological Advances:Genes · 2022Article
- Development and validation of a novel circular RNA as an independent prognostic factor in acute myeloid leukemia.BMC medicine · 2021Article
- Prognostic Nomogram for Acute Myeloid Leukemia Patients With Biallelic CEBPA Mutations.Frontiers in oncology · 2021Article
- Two NovelBalkan journal of medical genetics : BJMG · 2020Article
- The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.International journal of hematology · 2020Article
- Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).Blood · 2020Review
- Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact.PloS one · 2020Article
- Genetic heterogeneity of cytogenetically normal AML with mutations ofBlood advances · 2018Article
- MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia.Journal of translational medicine · 2018Article
- Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.Frontiers in pharmacology · 2017Review
- Molecular landscape in acute myeloid leukemia: where do we stand in 2016.Cancer biology & medicine · 2016Article
- Pseudogene BMI1P1 expression as a novel predictor for acute myeloid leukemia development and prognosis.Oncotarget · 2016Article
- Molecular Genetic Markers in Acute Myeloid Leukemia.Journal of clinical medicine · 2015Review
- Selective inhibitors of nuclear export (SINE) in hematological malignancies.Experimental hematology & oncology · 2015Article
- Higher Expression ofTechnology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to analyze the long-term survival of AML patients with CEBPA mutations. PATIENTS AND
methodsWe investigated 88 AML patients with a median age of 61 years and (1) cytogenetically normal AML (CN-AML), (2) monoallelic (moCEBPA) or biallelic (biCEBPA) CEBPA mutation, and (3) intensive induction treatment. 60/88 patients have been described previously with a shorter follow-up.
resultsMedian follow-up time was 9.8 years (95% CI: 9.4-10.1 years) compared to 3.2 and 5.2 years in our former analyses. Patients with biCEBPA mutations survived significantly longer compared to those with moCEBPA (median overall survival (OS) 9.6 years vs. 1.7 years, p = 0.008). Patients ≤ 60 years and biCEBPA mutations showed a favorable prognosis with a 10-year OS rate of 81%.
conclusionsIn this long-term observation we confirmed the favorable prognostic outcome of patients with biCEBPA mutations compared to moCEBPA-mutated CN-AML. The high probability of OS (81%) in younger patients is helpful to guide intensity of postremission therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.